TG Therapeutics announced positive topline results from the global UNITY-CLL Phase 3 trial evaluating the combination of umbralisib plus ublituximab […]
MD Anderson Cancer Center led a new cell-based immunotherapy clinical trial demonstrated powerfully positive results for 11 patients with either […]
A drug developed at Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute […]
The U.S. FDA granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or […]
A Phase I clinical trial, which has focused on patients with chronic lymphocytic leukemia (CLL) and a half dozen patients […]
NHS Scotland has accepted the use of combination-free treatment VENCLYXTO® (venetoclax) plus rituximab for people with previously treated Chronic Lymphocytic […]
OncLive interviews Jennifer A. Woyach, MD, on the current research and treatment spectrum for chronic lymphocytic leukemia (CLL). Dr. Woyach, an […]
Recently, a study known as ACE CL-309 (or ASCEND) reported success in their clinical trial on a drug called Calquence […]
Nicole Lamanna, investigator with New York-Presbyterian/Columbia University Medical Center was highlighted recently in Cure Today by Kristie L. Kahl. Ms. […]
Follow the link to Targeted Oncology for a breakdown of advances in treating chronic lymphocytic leukemia (CLL) as new agents, […]
